FOLH1 and prostate carcinoma: In the last decade, positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA) has become the preferred diagnostic test of choice for restaging patients with biochemical recurrence (BR) of prostate cancer (PCa) ((Trabulsi et al. 2020).